Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT | Synapse
August 1, 2024Open Access
Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Preclinical data supporting the combination of DNA base excision repair inhibitor (TRC102) with DNA alkylating agent (TMZ)